VLA15

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

14 competitors in Lyme Disease

#DrugCompanyPhaseTrials

1

Achromycin V

WWyeth-Lederle Vaccines

Approved

—2

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

43

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

24

Antabuse

Teva

Phase 2

15

Antibiotics

MMelinta Therapeutics, Inc.

Phase 3

16

VLA15

Pfizer

Phase 3

37

Psilocybin

COMPASS Pathways

Phase 1

18

Ceftriaxone Treatment

NNantes University Hospital

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Lyme disease3 trials

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

Recruiting·Pfizer·Phase 3·NCT07226882·200 enrolled

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Active, not recruiting·Pfizer·Phase 3·NCT05477524·12,547 enrolled

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Completed·Pfizer·Phase 3·NCT05634811·3,549 enrolled

Immunogenicity2 trials

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Completed·Pfizer·Phase 1·NCT03010228·179 enrolled

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Completed·Pfizer·Phase 2·NCT03769194·572 enrolled

Pediatric1 trial

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Completed·Pfizer·Phase 2·NCT04801420·625 enrolled

Vaccine1 trial

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

Completed·Pfizer·Phase 2·NCT03970733·246 enrolled

Details

Drug Info

Related News